New Board after Annual General Meeting

Oslo 11.05.2012 - Bionor Pharma`s Shareholders Voted Industry Experts Steen Krøyer, Jerry Zeldis and Benedicte Fossum to its Board of Directors at Annual General Meeting

Updated company presentation

Successfully results from clinical study with Vacc-4x and Endocine

Oslo 10.05.2012 - Successful Immunization and Safety Documented in Nasal Administration Study of the HIV Vaccine Vacc-4x together with Endocine

Nominations for Annual General Meeting of Bionor Pharma ASA 11 May 2012

Oslo 04.05.2012 - Bionor Pharma ASA announced today the Nomination Committee`s recommended candidates for the Board of Directors and the Nomination Committee at the Company`s Ordinary General Meeting 11 May.

Meldepliktig handel

Oslo, 27. april 2012 Marianne Furru, styremedlem i Bionor Pharma ASA har i dag kjøpt 100.000 aksjer

Innkalling til ordinær generalforsamling i Bionor Pharma ASA 11.05.2012

Oslo, 20.04.2012 - Den ordinære generalforsamlingen i Bionor Pharma ASA vil bli avholdt fredag 11. mai 2012 klokken 10.00 i Kronprinsesse Märthas plass 1, 2. etg., Oslo.

Bionor Researchers to Present Data on Vacc-4x Phase IIB Trial at World Vaccine Congress, Washington, DC

[Washington, DC -- 12 April 2012] Researchers from Bionor Pharma have been invited to present data at the World Vaccine Congress, on 13 April 2012.

Bionor Pharma Nominates Celgene`s Jerome Zeldis, MD, PhD, to Board of Directors

Oslo 11.04.2012 - Bionor Pharma (OSE: BIONOR) today announced thatJerome ("Jerry") Zeldis, MD, PhD, has been nominated by the Company's ElectionCommittee to its Board of Directors.

Results from Nasal Administration Study of HIV Vaccine Vacc-4x and Endocine Expected First Half of May

Oslo 10.04.2012 - Bionor Pharma ASA (OSE: BIONOR) today announces that the placebo controlled study of nasally administered HIV therapeutic vaccine Vacc-4x in combination with Eurocine Vaccines` Endocine has been finalized in Q1 as planned and previously communicated. 24 patients were included, and 23 completed the study. No serious adverse events have been reported.

Mandatory notification of trade

Oslo 06.03.2012 - Consultant for Bionor Pharma ASA, David Sheon, has yesterday purchased 7,500 Bionor shares at an average of NOK 2.93 per share.

FOURTH QUARTER AND FULL-YEAR RESULTS 2011

Oslo, 17.02.12 - Bionor Pharma ASA (OSE: BIONOR) today announced financial results for fourth quarter and full year 2011 and provided highlights of the key developments during the fourth quarter, current status and outlook.

Results for viral load on Vacc-4x

Oslo 15.02.2012 - With final review of phase IIb viral load data completed, researchers confirm statistically significant reduction of HIV viral load on Vacc-4x compared to placebo

With Final Documentation Submitted for International Patent Applications, Bionor Sees Promise of Two Core Platform Technologies

Oslo 23.01.2012 - Bionor Pharma ASA today announced that its submission has been completed for two applications of Intellectual Property that will provide general platform protection for the Company’s development of peptide vaccines for cellular immunity (such as the HIV therapeutic vaccine Vacc-4x) and humoral immunity (such as the HIV therapeutic / preventive vaccine Vacc-C5).

Bionor Pharma Strengthens International Team to Expedite Development and Commercialization of its Vaccines

Oslo 11.01.2012 - Bionor Pharma ASA today announcedhiring David Sheon, President at WHITECOAT Strategies, Washington DC, USA, on aconsultancy basis to further strengthen the management team throughinternational representation. David has over 20 years of experience consultingto biotechnology and pharmaceutical companies worldwide.

Researchers Study Nasal Administration of Bionor Pharma’s Therapeutic HIV Vaccine in Fully Enrolled Trial

Oslo 04.01.2012 - Researchers Study Nasal Administration of Bionor Pharma’s Therapeutic HIV Vaccine Vacc-4x Combined with Eurocine Vaccines’ Endocine™ in Fully Enrolled Trial; New Treatment Option Would Offer Easier Treatment Access for HIV Patients Globally.